BioNTech SE (NASDAQ:BNTX) to Post Q1 2024 Earnings of $1.26 Per Share, HC Wainwright Forecasts

BioNTech SE (NASDAQ:BNTX) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of BioNTech in a report issued on Wednesday, April 17th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of $1.26 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $107.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2024 earnings at ($1.99) EPS, Q3 2024 earnings at ($2.22) EPS, Q4 2024 earnings at $0.79 EPS and FY2024 earnings at ($2.15) EPS.

BNTX has been the subject of a number of other reports. Oppenheimer began coverage on BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating for the company. The Goldman Sachs Group cut their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. BMO Capital Markets dropped their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. Finally, UBS Group cut their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $120.40.

BioNTech Price Performance

Shares of BioNTech stock opened at $88.01 on Monday. The firm has a market cap of $20.92 billion, a PE ratio of 21.36 and a beta of 0.23. The business has a 50-day moving average price of $91.09 and a 200 day moving average price of $96.98. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of the business. CWM LLC raised its holdings in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after acquiring an additional 217 shares during the period. GAMMA Investing LLC boosted its holdings in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. Frazier Financial Advisors LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $30,000. Covestor Ltd purchased a new stake in shares of BioNTech in the 3rd quarter valued at approximately $32,000. Finally, First Horizon Advisors Inc. acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.